1492 Capital Management LLC Ligand Pharmaceuticals Inc Transaction History

1492 Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 06, 2019	SELL	$107.38 - $129.34 $862,798 - $1.04 Million	-8,035 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$105.93 - $142.47 $83,684 - $112,551	-790 Reduced 8.95%	8,035 $1.01 Million
Q4 2018 Feb 14, 2019	SELL	$128.36 - $272.13 $86,257 - $182,871	-672 Reduced 7.08%	8,825 $1.2 Million
Q3 2018 Nov 14, 2018	SELL	$211.18 - $274.49 $13,726 - $17,841	-65 Reduced 0.68%	9,497 $2.61 Million
Q2 2018 Aug 14, 2018	SELL	$150.77 - $207.98 $22,615 - $31,197	-150 Reduced 1.54%	9,562 $1.98 Million
Q4 2017 Feb 14, 2018	SELL	$128.36 - $147.04 $10,012 - $11,469	-78 Reduced 0.8%	9,712 $1.33 Million
Q3 2017 Nov 09, 2017	BUY	$120.91 - $137.94 $1.18 Million - $1.35 Million	9,790	9,790 $1.33 Million

247

17.5M

61K

7.8K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.69B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of 1492 Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on 1492 Capital Management LLC with notifications on news.